Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/15094
Título
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Autor(es)
Del Fresno, Carlos | García-Arriaza, Juan | Martínez-Cano, Sarai | Heras-Murillo, Ignacio CNIC | Jarit-Cabanillas, Aitor | Amores-Iniesta, Joaquin CNIC | Brandi, Paola CNIC | Dunphy, Gillian | Suay-Corredera, Carmen CNIC | Pricolo, Maria Rosaria | Vicente, Natalia | López-Perrote, Andrés | Cabezudo, Sofía | González-Corpas, Ana | Llorca, Oscar | Alegre-Cebollada, Jorge CNIC | Garaigorta, Urtzi | Gastaminza, Pablo | Esteban, Mariano | Sancho, David CNIC
Fecha de publicación
2021-11
Cita
Front Immunol . 2021 Nov 18;12:748103
Idioma
Inglés
Tipo de documento
journal article
Resumen
COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity.
MESH
Administration, Mucosal | Animals | Antibodies, Viral | Bacteria | CD8-Positive T-Lymphocytes | COVID-19 | COVID-19 Vaccines | Immunity, Heterologous | Immunity, Innate | Immunogenicity, Vaccine | Immunoglobulin A | Immunologic Factors | Mice | SARS-CoV-2 | Vaccination
Versión en línea
DOI
Aparece en las colecciones